• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Avantor Inc.

    2/13/25 3:54:35 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Avantor, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    05352A100

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    05352A100


    1Names of Reporting Persons

    Dodge & Cox
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    93,939,170.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    99,145,770.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    99,145,770.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Avantor, Inc.
    (b)Address of issuer's principal executive offices:

    Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road, Radnor, Pennsylvania 19087
    Item 2. 
    (a)Name of person filing:

    Dodge & Cox
    (b)Address or principal business office or, if none, residence:

    555 California Street 40th Floor, San Francisco, CA 94104
    (c)Citizenship:

    California, USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    05352A100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    99,145,770
    (b)Percent of class:

    14.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    93,939,170

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    99,145,770

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Avantor, Inc. Dodge & Cox Stock Fund, an investment company registered under the Investment Company Act of 1940, has an interest of 66,841,215 or 9.8%, of the class of securities reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Dodge & Cox
     
    Signature:/S/ Katherine M. Primas
    Name/Title:Chief Compliance Officer
    Date:02/13/2025
    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Laboratory Solutions Walker Corey was granted 162,866 shares, increasing direct ownership by 229% to 234,001 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:49 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carethers John was granted 17,100 shares, increasing direct ownership by 59% to 45,858 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:39 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP & Chief Accounting Officer Eck Steven W was granted 20,358 shares, increasing direct ownership by 51% to 59,929 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:27 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/9/25 4:51:58 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Massaro Joseph R bought $99,630 worth of shares (8,100 units at $12.30), increasing direct ownership by 30% to 35,038 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      4/29/25 5:58:52 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $312,500 worth of shares (25,000 units at $12.50) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      4/29/25 5:58:40 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Financials

    Live finance-specific insights

    See more
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Reports First Quarter 2025 Results

      Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

      4/25/25 6:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Report First Quarter 2025 Earnings on Friday, April 25, 2025

      RADNOR, Pa., March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

      3/28/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

      RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

      11/6/24 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

      NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

      7/23/24 7:17:00 PM ET
      $APO
      $AVTR
      $HIBB
      $QDEL
      Investment Managers
      Finance
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      11/14/24 1:28:33 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      8/9/24 3:22:24 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      8/7/24 4:09:12 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avantor downgraded by Goldman with a new price target

      Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

      4/29/25 8:05:35 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by TD Cowen with a new price target

      TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

      4/28/25 8:32:10 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by Stifel with a new price target

      Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00

      4/28/25 8:31:49 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

      RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

      5/2/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Reports First Quarter 2025 Results

      Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

      4/25/25 6:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    SEC Filings

    See more
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      5/12/25 5:16:45 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      4/28/25 8:29:56 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Avantor Inc.

      10-Q - Avantor, Inc. (0001722482) (Filer)

      4/25/25 9:00:12 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials